Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Boehringer Ingelheim and MacroGenics have formed a global alliance to discover, develop and commercialise antibody-based therapeutics which may span multiple therapeutic areas, including immunology, oncology, respiratory, cardiometabolic and infectious diseases.
Subscribe to our email newsletter
The drugs to be developed under the alliance will be based on MacroGenics’ Dual-Affinity Re-Targeting (DART) platform and will be directed against up to 10 combinations of molecular targets.
The DART platform is a bispecific antibody technology that enables the generation of highly stable antibody-based therapeutic molecules that can simultaneously target two different antigens.
As per the contract, Boehringer Ingelheim and MacroGenics will be responsible for discovery and certain preclinical activities.
However, Boehringer Ingelheim will have sole responsibility for all subsequent preclinical, clinical, regulatory, commercial and manufacturing activities for any DART-based product resulting from the collaboration.
During the first three years of the collaboration, MacroGenics expects to receive payments of about $60m, which includes an upfront cash payment, annual maintenance fees, R&D funding, and near-term research-based milestones, and may also receive tiered royalties on net product sales.
MacroGenics has also the option to co-promote certain DART products in the US.
In addition, MacroGenics may be eligible to receive development, regulatory and commercial milestone payments that can reach up to $210m for each of the ten DART programs in case of full commercial success of multiple DART products.